These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 22047791)

  • 1. Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment.
    Levy I; Horvath A; Azevedo M; de Alexandre RB; Stratakis CA
    Curr Opin Pharmacol; 2011 Dec; 11(6):689-97. PubMed ID: 22047791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PDE inhibitors: a new approach to treat metabolic syndrome?
    Lugnier C
    Curr Opin Pharmacol; 2011 Dec; 11(6):698-706. PubMed ID: 22018840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclic nucleotide phosphodiesterases: critical modulators of endocrine, metabolic, and cardiovascular function and appealing therapeutic targets.
    Manganiello V
    Curr Opin Pharmacol; 2011 Dec; 11(6):646-8. PubMed ID: 22079477
    [No Abstract]   [Full Text] [Related]  

  • 4. Porcine detrusor cyclic nucleotide phosphodiesterase isoenzymes: characterization and functional effects of various phosphodiesterase inhibitors in vitro.
    Truss MC; Uckert S; Stief CG; Schulz-Knappe P; Hess R; Forssmann WG; Jonas U
    Urology; 1995 May; 45(5):893-901. PubMed ID: 7747383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?
    Kass DA
    Circulation; 2007 Jul; 116(3):233-5. PubMed ID: 17638937
    [No Abstract]   [Full Text] [Related]  

  • 6. Phosphodiesterases and regulation of female reproductive function.
    Conti M
    Curr Opin Pharmacol; 2011 Dec; 11(6):665-9. PubMed ID: 22019564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.
    Ahmad F; Murata T; Shimizu K; Degerman E; Maurice D; Manganiello V
    Oral Dis; 2015 Jan; 21(1):e25-50. PubMed ID: 25056711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pig aortic endothelial-cell cyclic nucleotide phosphodiesterases. Use of phosphodiesterase inhibitors to evaluate their roles in regulating cyclic nucleotide levels in intact cells.
    Souness JE; Diocee BK; Martin W; Moodie SA
    Biochem J; 1990 Feb; 266(1):127-32. PubMed ID: 2155604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of PDE4 structure on inhibitor selectivity across PDE families.
    Ke H
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle.
    Torphy TJ; Cieslinski LB
    Mol Pharmacol; 1990 Feb; 37(2):206-14. PubMed ID: 2154670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
    Marcoz P; Prigent AF; Lagarde M; Nemoz G
    Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclic GMP and regulation of cyclic nucleotide hydrolysis.
    Sonnenburg WK; Beavo JA
    Adv Pharmacol; 1994; 26():87-114. PubMed ID: 8038108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic nucleotide phosphodiesterase assay technology.
    MacKenzie SJ; Hastings SF; Wells C
    Curr Protoc Pharmacol; 2010 Jun; Chapter 3():Unit 3.12. PubMed ID: 22294369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure.
    Stehlik J; Movsesian MA
    Expert Opin Investig Drugs; 2006 Jul; 15(7):733-42. PubMed ID: 16787138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Modern representations of multiple forms of cyclic nucleotide phosphodiesterases in mammalian tissues].
    Medvedeva MV
    Biokhimiia; 1995 Mar; 60(3):364-86. PubMed ID: 7734612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resolution of soluble cyclic nucleotide phosphodiesterase isoenzymes, from liver and hepatocytes, identifies a novel IBMX-insensitive form.
    Lavan BE; Lakey T; Houslay MD
    Biochem Pharmacol; 1989 Nov; 38(22):4123-36. PubMed ID: 2480793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
    Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
    Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for the activity of five adenosine-3',5'-monophosphate-degrading phosphodiesterase isozymes in the adult rat neocortex.
    Sutor B; Mantell K; Bacher B
    Neurosci Lett; 1998 Aug; 252(1):57-60. PubMed ID: 9756358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors.
    Schoeffter P; Lugnier C; Demesy-Waeldele F; Stoclet JC
    Biochem Pharmacol; 1987 Nov; 36(22):3965-72. PubMed ID: 2825708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isoenzyme-selective cyclic nucleotide phosphodiesterase inhibitors: effects on airways smooth muscle.
    Raeburn D; Advenier C
    Int J Biochem Cell Biol; 1995 Jan; 27(1):29-37. PubMed ID: 7757880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.